1360 Treatment with a novel hexavalent OX40 agonist remodels the tumor microenvironment to favor anti-tumor immunity in mice

Abstract

BackgroundT cell costimulation through tumor necrosis factor receptors, such as OX40 (CD134), provides critical survival and differentiation signals. Although OX40 agonists were tested in early-phase clinical trials, their therapeutic efficacy...